Search Results for "fluid"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for fluid. Results 31 to 40 of 206 total matches.
Balfaxar: Another Four-Factor PCC for Warfarin Reversal
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
factors rapidly, but
use of FFP requires blood group typing, thawing, and
use of large volumes of fluid ...
Balfaxar (Octapharma), a human plasma-derived
four-factor prothrombin complex concentrate (PCC),
has been approved by the FDA for rapid reversal of
warfarin anticoagulation in adults who require an
urgent surgical/invasive procedure. It is the second
four-factor PCC to become available in the US;
Kcentra, which has been available since 2013, is
approved for the same indication and for urgent
reversal of warfarin anticoagulation in adults with
acute major bleeding. Balfaxar is marketed in Canada
and Europe as Octaplex.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):31-2 doi:10.58347/tml.2024.1696d | Show Introduction Hide Introduction
Colonoscopy Preparations
The Medical Letter on Drugs and Therapeutics • Jan 21, 2013 (Issue 1408)
the safest choice for
patients who cannot tolerate a fluid load, such as
those with heart failure, renal ...
Colonoscopy remains the preferred method of colorectal
cancer screening. Many patients consider
cleansing the bowel in preparation for colonoscopy
the most unpleasant part of the procedure, but inadequate
bowel preparation significantly lowers the diagnostic
yield.
Intravenous Ciprofloxacin
The Medical Letter on Drugs and Therapeutics • Aug 09, 1991 (Issue 850)
, bronchial secretions, sputum, lymph, peritoneal fluid, lung, skin, bone,
and prostate. CSF and eye ...
Ciprofloxacin, previously available orally (Cipro - Medical Letter, 30:11, 1988) and for ophthalmic use (Ciloxan - Medical Letter, 33:52, May 31, 1991), is now the first fluoroquinolone antibiotic to become available in the USA in an intravenous (IV) formulation. Cipro I.V. (Miles) is being promoted as an alternative to third-generation cephalosporins, aminoglycosides, and other drugs used for treatment of serious infections.
Colon Cleansing
The Medical Letter on Drugs and Therapeutics • May 18, 2009 (Issue 1312)
or colon hydrotherapy) is intended to flush
the entire length of the colon. The fluid may be plain ...
Web sites and blogs are advising patients that periodic "cleansing" of the colon is necessary to rid the body of toxins.
Nusinersen (Spinraza) for Spinal Muscular Atrophy
The Medical Letter on Drugs and Therapeutics • Mar 27, 2017 (Issue 1517)
to be distributed from the
cerebrospinal fluid to the target central nervous
system tissues.
CLINICAL STUDIES ...
The FDA has approved nusinersen (Spinraza – Biogen)
for treatment of spinal muscular atrophy (SMA), a
hereditary neurodegenerative disease that occurs in
about one in every 10,000 births. It is the first drug to
be approved in the US for this indication.
In Brief: Oxytrol OTC
The Medical Letter on Drugs and Therapeutics • Sep 16, 2013 (Issue 1425)
, including fluid
schedules, timed voiding, pelvic exercises, and urge
suppression, is usually tried first ...
The transdermal patch formulation of the anticholinergic drug oxybutynin (Oxytrol – Watson) is now available over the counter (OTC) as Oxytrol for Women (MSD) for use in women with overactive bladder (OAB). It is the first treatment for OAB to become available OTC. Oxybutynin remains available only by prescription for men.OAB, characterized by symptoms of urgency, frequency, and incontinence with no obvious cause, occurs mainly in older women.1 Behavioral modification, including fluid schedules, timed voiding, pelvic exercises, and urge suppression, is usually tried first.Anticholinergic...
Diclofenac
The Medical Letter on Drugs and Therapeutics • Dec 02, 1988 (Issue 780)
in plasma; synovial fluid concentrations were higher
and lasted longer than plasma concentrations (MD ...
Diclofenac sodium (Voltaren - Geigy), a nonsteroidal anti-inflammatory drug (NSAID) available in some countries since 1974, was recently introduced in the USA for treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. It is being promoted as 'The number one prescribed antiarthritic in the world.'
Treatment of Pressure Ulcers
The Medical Letter on Drugs and Therapeutics • Feb 23, 1990 (Issue 812)
a fluid-like surface on which the patient
floats with less than 10 mm Hg pressure at any contact point ...
Pressure is the most critical factor in the development of pressure ulcers; high pressure applied constantly for two hours produces irreversible tissue ischemia and necrosis. Malnutrition, fecal and urinary incontinence, fractures, and a low serum albumin may be additional risk factors. Frequent turning and mobilization of patients, relieving pressure and allowing tissue reoxygenation, are the most effective means of prevention and treatment (PS Goode and RM Allman, Med Clin North Am, 73:1511, Nov 1989).
Rosiglitazone/Glimepiride (Avandaryl) for Diabetes
The Medical Letter on Drugs and Therapeutics • Mar 13, 2006 (Issue 1230)
al. Thiazolidinedione use, fluid retention, and
congestive heart failure. Diabetes Care 2004; 27 ...
Avandaryl, a new fixed-dose tablet combining the thiazolidinedione rosiglitazone (Avandia) and the sulfonylurea glimepiride (Amaryl, and others), was recently approved by the FDA for treatment of type 2 diabetes. It is approved for patients already taking a combination of rosiglitazone and a sulfonylurea or those not adequately controlled on rosiglitazone or sulfonylurea monotherapy. Rosiglitazone is also available in a fixed-dose combination with metformin (Avandamet). Most patients with type 2 diabetes eventually require 2 drugs with different mechanisms to control...
Comparison Table: Some Drugs for Gout (online only)
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
, fluid retention, and
hypertension and renal failure (particularly in
older patients)
Small increases ...
View the Comparison Table: Some Drugs for Gout
Med Lett Drugs Ther. 2023 Oct 30;65(1688):e176-9 doi:10.58347/tml.2023.1688c | Show Introduction Hide Introduction